Group 1 - MediWound reported a quarterly loss of $0.07 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.65, representing an earnings surprise of 89.23% [1] - The company posted revenues of $3.96 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 22.39%, and down from $4.96 million a year ago [2] - MediWound shares have increased approximately 17.3% since the beginning of the year, outperforming the S&P 500's gain of 1% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.67 on revenues of $5.74 million, and for the current fiscal year, it is -$2.84 on revenues of $24.36 million [7] - The Zacks Industry Rank for Medical - Drugs is currently in the top 21% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates